A piperazine drug with potential applications in treating schizophrenia and bipolar disorder.
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the USA. It was approved by the U.S. Food and Drug Administration for treatment of schizophrenia on October 28, 2010 after a review that found that two of the four Phase III clinical trials supported efficacy, while one showed only marginal efficacy and one was not interpretable because of high drop-out rates.It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision as favourable on October 15, 2012. Lurasidone was approved by the U.S. FDA on July 1, 2013 for treatment of depressive episodes associated with Bipolar I Disorder in adults when used alone or in combination with lithium or valproate.
The numerical value of lurasidone in Chaldean Numerology is: 1
The numerical value of lurasidone in Pythagorean Numerology is: 1
Images & Illustrations of lurasidone
Find a translation for the lurasidone definition in other languages:
Select another language: